Calici and Yokohama, Japan-based CellFree Sciences (CFS) announced that they have formalized a partnership. The partnership will combine Calici’s AI modeling and drug candidate optimization expertise with CFS’s molecular interaction analysis and proteomics profiling services.
The primary goal of this collaboration is to achieve groundbreaking progress in infectious diseases, metabolic disorders, and cancer treatments through in silico and experimental protein interaction studies, target validation/off-target analysis, and mechanism of action studies. The two companies will also serve as mutual agencies in Korea and Japan to facilitate cross-border collaboration and improve customer access to innovative technologies. Through this, the two companies will strengthen their shared mission to address unmet medical needs worldwide.
Satoshi Ozawa, CEO of CFS, said, “Kalisi’s AI platform provides easy, fast, and accurate results for protein structure-based compound discovery. It is innovative and reliable as it has proven reliable data quality in multiple projects. CFS’s MaZiQ array® will verify the results of AI-designed drug candidates and make experimental success meaningful. This will enable us to provide higher added value to new drug development companies.”
“This partnership represents a new era in drug development, and we aim to create synergy by combining the unique technologies of both companies to develop more efficient new drugs and disease treatments,” said Jae-Moon Choi, CEO of Calici. “Together, we expect to be able to provide groundbreaking solutions to both countries more quickly and efficiently.”
You must be logged in to post a comment.